Terns CEO Amy Burroughs talks cancer drug trial win

Core Insights - The company, Turns Pharmaceuticals, is developing a new drug, Turn 701, for chronic myeloid leukemia (CML) that has shown approximately three times better efficacy than the current standard of care [1][3] - The drug has achieved a 75% major molecular response rate in patients who have undergone two or more prior treatments, indicating significant potential for those with limited options [3] - The company plans to initiate pivotal trials by the end of 2026, aiming to bring the drug to market soon [4] Market Potential - The current leading drug for CML is projected to reach peak sales of $4 billion, and the new drug is expected to have a larger addressable market due to its superior efficacy and the chronic nature of the disease [5][6] - Investors are optimistic about the drug's potential, contributing to a valuation close to $5 billion for the company [5] Development Focus - The company is primarily focused on bringing Turn 701 to market, with plans to share more information about additional assets in the pipeline in the future [6][7]